XML 96 R32.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Segment Information | Segment Information We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee. Revenues by product are summarized as follows:
| For the Years Ended December 31,
| 2017 |  | 2016 |  | 2015
(In millions) | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 3,294.0 |  |  | $ | 920.0 |  |  | $ | 4,214.0 |  |  | $ | 3,169.4 |  |  | $ | 798.7 |  |  | $ | 3,968.1 |  |  | $ | 2,908.2 |  |  | $ | 730.2 |  |  | $ | 3,638.4 |
AVONEX | 1,593.6 |  |  | 557.9 |  |  | 2,151.5 |  |  | 1,675.3 |  |  | 638.2 |  |  | 2,313.5 |  |  | 1,790.2 |  |  | 840.0 |  |  | 2,630.2 |
PLEGRIDY | 295.5 |  |  | 198.8 |  |  | 494.3 |  |  | 305.0 |  |  | 176.7 |  |  | 481.7 |  |  | 227.1 |  |  | 111.4 |  |  | 338.5 |
TYSABRI | 1,113.8 |  |  | 859.3 |  |  | 1,973.1 |  |  | 1,182.9 |  |  | 780.9 |  |  | 1,963.8 |  |  | 1,103.1 |  |  | 783.0 |  |  | 1,886.1 |
FAMPYRA | — |  |  | 91.6 |  |  | 91.6 |  |  | — |  |  | 84.9 |  |  | 84.9 |  |  | — |  |  | 89.7 |  |  | 89.7 |
ZINBRYTA | — |  |  | 52.7 |  |  | 52.7 |  |  | — |  |  | 7.8 |  |  | 7.8 |  |  | — |  |  | — |  |  | — |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 657.0 |  |  | 226.7 |  |  | 883.7 |  |  | 4.6 |  |  | — |  |  | 4.6 |  |  | — |  |  | — |  |  | — |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | 42.2 |  |  | 6.2 |  |  | 48.4 |  |  | 445.2 |  |  | 68.0 |  |  | 513.2 |  |  | 308.3 |  |  | 11.4 |  |  | 319.7 |
ALPROLIX | 21.0 |  |  | 5.0 |  |  | 26.0 |  |  | 268.0 |  |  | 65.7 |  |  | 333.7 |  |  | 208.9 |  |  | 25.6 |  |  | 234.5 |
Other product revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 39.6 |  |  | 39.6 |  |  | — |  |  | 45.9 |  |  | 45.9 |  |  | — |  |  | 51.4 |  |  | 51.4 |
BENEPALI | — |  |  | 370.8 |  |  | 370.8 |  |  | — |  |  | 100.6 |  |  | 100.6 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 9.0 |  |  | 9.0 |  |  | — |  |  | 0.1 |  |  | 0.1 |  |  | — |  |  | — |  |  | — |
Total product revenues | $ | 7,017.1 |  |  | $ | 3,337.6 |  |  | $ | 10,354.7 |  |  | $ | 7,050.4 |  |  | $ | 2,767.5 |  |  | $ | 9,817.9 |  |  | $ | 6,545.8 |  |  | $ | 2,642.7 |  |  | $ | 9,188.5 |
Geographic Information The following tables contain certain financial information by geographic area:
December 31, 2017 (In millions) | U.S. |  | Europe |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 7,017.1 |  |  | $ | 2,844.8 |  |  | $ | 160.1 |  |  | $ | 332.7 |  |  | $ | 10,354.7 |
Revenues from anti-CD20 therapeutic programs | $ | 1,475.6 |  |  | $ | 0.6 |  |  | $ | — |  |  | $ | 83.0 |  |  | $ | 1,559.2 |
Other revenues from external customers | $ | 249.5 |  |  | $ | 67.8 |  |  | $ | 42.7 |  |  | $ | — |  |  | $ | 360.0 |
Long-lived assets | $ | 1,226.9 |  |  | $ | 1,948.2 |  |  | $ | 5.2 |  |  | $ | 2.1 |  |  | $ | 3,182.4 |
December 31, 2016 (In millions) | U.S. |  | Europe |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 7,050.4 |  |  | $ | 2,237.2 |  |  | $ | 217.3 |  |  | $ | 313.0 |  |  | $ | 9,817.9 |
Revenues from anti-CD20 therapeutic programs | $ | 1,249.5 |  |  | $ | 1.9 |  |  | $ | — |  |  | $ | 63.1 |  |  | $ | 1,314.5 |
Other revenues from external customers | $ | 224.7 |  |  | $ | 71.5 |  |  | $ | 20.2 |  |  | $ | — |  |  | $ | 316.4 |
Long-lived assets | $ | 1,272.3 |  |  | $ | 1,221.1 |  |  | $ | 7.0 |  |  | $ | 1.4 |  |  | $ | 2,501.8 |
December 31, 2015 (In millions) | U.S. |  | Europe |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 6,545.8 |  |  | $ | 2,165.7 |  |  | $ | 143.7 |  |  | $ | 333.3 |  |  | $ | 9,188.5 |
Revenues from anti-CD20 therapeutic programs | $ | 1,269.8 |  |  | $ | 3.5 |  |  | $ | — |  |  | $ | 65.9 |  |  | $ | 1,339.2 |
Other revenues from external customers | $ | 142.0 |  |  | $ | 31.2 |  |  | $ | 62.9 |  |  | $ | — |  |  | $ | 236.1 |
Long-lived assets | $ | 1,296.5 |  |  | $ | 881.7 |  |  | $ | 7.7 |  |  | $ | 1.7 |  |  | $ | 2,187.6 |
Revenues from Anti-CD20 Therapeutic Programs Approximately 13%, 11% and 12% of our total revenues in 2017, 2016 and 2015, respectively, are derived from our collaboration agreement with Genentech. For additional information on our collaboration with Genentech, please read Note 20, Collaborative and Other Relationships, to these consolidated financial statements. Significant Customers We recorded revenues from two wholesalers accounting for 34% and 21% of gross product revenues in 2017, 35% and 22% of gross product revenues in 2016, and 34% and 26% of gross product revenues in 2015, respectively. Other As of December 31, 2017, 2016 and 2015, approximately $1,215.7 million, $545.5 million and $161.5 million, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland. As of December 31, 2017, 2016 and 2015, approximately $707.1 million, $643.6 million and $684.9 million, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, Property, Plant and Equipment, to these consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration